JPH0354939B2 - - Google Patents
Info
- Publication number
- JPH0354939B2 JPH0354939B2 JP61263630A JP26363086A JPH0354939B2 JP H0354939 B2 JPH0354939 B2 JP H0354939B2 JP 61263630 A JP61263630 A JP 61263630A JP 26363086 A JP26363086 A JP 26363086A JP H0354939 B2 JPH0354939 B2 JP H0354939B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- dimethylaminoethanol
- hydrochloride
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 25
- HETCEOQFVDFGSY-UHFFFAOYSA-N Isopropenyl acetate Chemical compound CC(=C)OC(C)=O HETCEOQFVDFGSY-UHFFFAOYSA-N 0.000 claims description 17
- CRYDUXLWJITARY-UHFFFAOYSA-N dimethyl(2-methylsulfonyloxyethyl)azanium;chloride Chemical compound Cl.CN(C)CCOS(C)(=O)=O CRYDUXLWJITARY-UHFFFAOYSA-N 0.000 claims description 17
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000003377 acid catalyst Substances 0.000 claims description 10
- 230000029936 alkylation Effects 0.000 claims description 10
- 238000005804 alkylation reaction Methods 0.000 claims description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 10
- 238000006640 acetylation reaction Methods 0.000 claims description 9
- 230000021736 acetylation Effects 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 6
- LHBHZALHFIQJGJ-CABCVRRESA-N (2s,3s)-3-hydroxy-2-(4-methoxyphenyl)-3,5-dihydro-2h-1,5-benzothiazepin-4-one Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](O)C(=O)NC2=CC=CC=C2S1 LHBHZALHFIQJGJ-CABCVRRESA-N 0.000 claims description 5
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical class CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 4
- WKLRIRQZTCFCSE-UHFFFAOYSA-N [2-(4-methoxyphenyl)-4-oxo-3,5-dihydro-2h-1,5-benzothiazepin-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1C1C(OC(C)=O)C(=O)NC2=CC=CC=C2S1 WKLRIRQZTCFCSE-UHFFFAOYSA-N 0.000 claims description 3
- 239000012345 acetylating agent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000397 acetylating effect Effects 0.000 claims 2
- 230000002152 alkylating effect Effects 0.000 claims 2
- 239000000243 solution Substances 0.000 description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- -1 2-dimethylaminoethyl halide Chemical class 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000000376 reactant Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 3
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 3
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 3
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- WKLRIRQZTCFCSE-SJORKVTESA-N [(2s,3s)-2-(4-methoxyphenyl)-4-oxo-3,5-dihydro-2h-1,5-benzothiazepin-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)NC2=CC=CC=C2S1 WKLRIRQZTCFCSE-SJORKVTESA-N 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- XZPLOMKLRYGXOZ-HOCLYGCPSA-N (2s,3s)-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-3-ol Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](O)C=NC2=CC=CC=C2S1 XZPLOMKLRYGXOZ-HOCLYGCPSA-N 0.000 description 1
- KHQWPNQLSKDWAR-CABCVRRESA-N (2s,3s)-3-(2-aminophenyl)sulfanyl-2-hydroxy-3-(4-methoxyphenyl)propanoic acid Chemical compound C1=CC(OC)=CC=C1[C@@H]([C@@H](O)C(O)=O)SC1=CC=CC=C1N KHQWPNQLSKDWAR-CABCVRRESA-N 0.000 description 1
- XNQWAVFYFJXSHD-VOMIJIAVSA-N (2s,3s)-5-[2-(dimethylamino)ethyl]-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4-one;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1[C@H]1[C@@H](O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 XNQWAVFYFJXSHD-VOMIJIAVSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 1
- AAAUVSWWQXTZAR-UHFFFAOYSA-N 3-chloro-n,n-dimethylbutan-1-amine Chemical compound CC(Cl)CCN(C)C AAAUVSWWQXTZAR-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- PPQXADXGECUTFI-UHFFFAOYSA-N 5h-1,5-benzothiazepin-4-one Chemical compound S1C=CC(=O)NC2=CC=CC=C21 PPQXADXGECUTFI-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002371 cardiac agent Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- XOPUORAQCYGJPT-UHFFFAOYSA-N methanesulfonic acid;hydrochloride Chemical compound Cl.CS(O)(=O)=O XOPUORAQCYGJPT-UHFFFAOYSA-N 0.000 description 1
- CVZUMGUZDAWOGA-VHSXEESVSA-N methyl (2r,3s)-3-(4-methoxyphenyl)oxirane-2-carboxylate Chemical compound COC(=O)[C@@H]1O[C@H]1C1=CC=C(OC)C=C1 CVZUMGUZDAWOGA-VHSXEESVSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯ãåŒïŒïŒ
ã®ïŒ2SïŒ3SïŒâïŒâã¢ã»ããã·âïŒâïŒïŒ®ïŒïŒ®â
ãžã¡ãã«ã¢ããâãšãã«ïŒâïŒâïŒïŒâã¡ããã·ã
ãšãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒâãã³ãŸã
ã¢ãŒãã³âïŒïŒ5HïŒãªã³ããã³ãã®é
žä»å å¡©ã®æ°
ãã補é æ¹æ³ã«é¢ããããã®äžè¬åãžã«ãã¢ãŒã
ïŒdiltiazemïŒã«ããåŒïŒïŒã®ååç©ã¯ã«ã«ã·ãŠ
ã æ®æ掻æ§ãæããå¿èè¬ã§ããã
åœæ¥çã«æ¢ç¥ã®ãå€ãã®ãžã«ãã¢ãŒã ã®è£œé æ¹
æ³ã«ãããŠãïŒâã¢ããâããªããšããŒã«ããã³
ãã©ã³ã¹ã¡ãã«ïŒâïŒïŒâã¡ããã·ããšãã«ïŒâãª
ãã·ã©ã³âïŒâã«ã«ããã·ã¬ãŒãã®åå¿ã«ããäž
å±€å€ãã®åå¿å·¥çšã«ãããŠè£œé ãããåŒïŒïŒ
ã®ïŒ2SïŒ3SïŒâïŒâïŒïŒâã¢ããããšãã«âããªïŒ
âïŒâããããã·âïŒâïŒïŒâã¡ããã·ããšãã«ïŒ
âããããªã³é
žãŸãã¯ãããã補é ãããåŒ
ïŒïŒ
ã®ïŒ2SïŒ3SïŒâïŒâããããã·âïŒâïŒïŒâã¡ã
ãã·ããšãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒâã
ã³ãŸãã¢ãŒãã³âïŒïŒ5HïŒâãªã³ãåºçºç©è³ªãšã
ãŠçšããããã
åŒïŒïŒã®ååç©ã®æã補é æ¹æ³ã«ããã°ãäŸ
ãã°ãã³ã¬ãªãŒç¹èš±ç¬¬159671å·æ现æžïŒãã«ã®ãŒ
ç¹èš±ç¬¬723035å·æ现æžïŒããã³åè¡ç©è¬åŠéèª
93ã729ïŒ1973ïŒããã³ãã«ããã€ã«ã»ã·ãã«ã»ã¢
ã¯ã¿ïŒHelv.Chim.ActaïŒ67ã916ïŒ1984ïŒã«ãã
ãŠãåŒïŒïŒã®ååç©ã®ã©ã»ãååç©ããŸãã¢ã«
ã«ãªéå±æ°ŽçŽ åç©ã奜ãŸããã¯æ°ŽçŽ åãããªãŠã
ã§çžåœããå¡©ã«å€æããåŸãããå¡©ãããã²ã³å
ïŒâãžã¡ãã«ã¢ãããšãã«ã奜ãŸããã¯å¡©åïŒâ
ãžã¡ãã«âã¢ãããšãã«ã§ã¢ã«ãã«åãã次ãã§
ã©ã»ãååç©ãšããŠåŸãããåŒïŒïŒ
ã®ïŒâïŒïŒâãžã¡ãã«ã¢ãããšãã«ïŒâïŒâããã
ãã·âïŒâïŒïŒâã¡ããã·ããšãã«ïŒâïŒïŒïŒâãž
ãããâïŒïŒïŒâãã³ãŸãã¢ãŒãã³âïŒïŒ5HïŒâ
ãªã³ãç¡æ°Žé
¢é
žã§ã¢ã»ãã«åãããäŸã«ããã°ã
ã¢ã«ãã«åå·¥çšã®åçã¯ãåºç¯å²ïŒ12.4ïŒ
ã84
ïŒ
ïŒå
ã§å€ãããããŠãã®æè¡çå®çŸåã«ã¯å€ã
ã®å°é£ã䌎ã€ããåŒïŒïŒã®ååç©ãã¢ããªã³åœ¢
ã«ãããã€å¡©åç©ã€ãªã³ãçµåãããããã«ãæ°Ž
çŽ åãããªãŠã ã®çã¢ã«éãå¿
èŠã§ãããæ°ŽçŽ å
ãããªãŠã ã¯ããã®åŒç«æ§ã®æ
ã«é±æ²¹ïŒ40ïŒ
ã50
ïŒ
ïŒäžã«è²¯èµãããåŸã€ãŠãåå¿æ··åç©ã«é±æ²¹ã®
çè·¡éã®ååšã¯é¿ããããªããæ²¹ã®çè·¡éã¯ãåŸ
ãããïŒâïŒïŒâãžã¡ãã«ã¢ãããšãã«ïŒâïŒâã
ãããã·âïŒâïŒïŒâã¡ããã·ããšãã«ïŒâïŒïŒïŒ
âãžãããâïŒïŒïŒâãã³ãŸãã¢ãŒãã³âïŒ
ïŒ5HïŒâãªã³ãããã®å¡©ã®åœ¢ã§æ°Žæ§çžã«å°å
¥ãã
ããšã«ãã€ãŠã®ã¿é€ãããšãã§ãããåå¿ã®ä»ã®
æ¬ ç¹ã¯ãã¢ã«ãã«åå·¥çšã«ãããŠãå¡©åïŒâãžã¡
ãã«ã¢ãããšãã«ãçšãããã®æ°ŽçŽ åãããªãŠã
ã®åèšã®æ§è³ªã®æ
ã«ç¡æ°Žææ©æº¶æ¶²ã«å ããããšã§
ãããå¡©åïŒâãžã¡ãã«ã¢ãããšãã«ãšãã«ã¯ã
ïŒãé äžå°Ÿãåå¿ã®éäžã§ïŒèªå·±åçŽåããããã
ãšãæ¢ç¥ã§ãããããã¯å€§èŠæš¡ã«ãããŠå°é£ãªå
é¡ãçããããªããªãã°ãåçŽååå¿ã®çæç©ã¯
ãšãŒãã«æº¶æ¶²ãŸãã¯ä»ã®äžæŽ»æ§æº¶åªããã€ãŠè£œé
ããã溶液ããæ²æ®¿ããããã«ãã€ãŠåå¿ã¯å¯ç
ç©åœ¢æã®æ¹åã«ç§»ããåèšã®ããã«ãåèšã®åŒäŸ
ã«ãããåŒïŒïŒã®ååç©ã¯ã90ãã100âã«ãã
ãŠç¡æ°Žé
¢é
žã«ãã€ãŠåŒïŒïŒã®æçµçæç©ã«å€æ
ãããããã®å·¥çšã¯äœãå°é£ããªãããã«æãã
ãããåŸãããåçããããã«80ïŒ
ã84ïŒ
ã§ã
ãããããéå°ã«çšããåå¿äœã®åçã«é¢ããé
¢
é
žã®ååšã«ãã€ãŠäžå±€å°é£ã«ãªãåé¡ããããã®
å·¥çšãããéçºãããå·¥æ¥çã«å¿çšã§ããæäœã®
å¿
èŠæ¡ä»¶ãå®å
šã«æºãããªãããšãåããã
åŒïŒïŒã®ååç©ã¯ããŸããšãŒãããç¹èš±åºé¡
第81234å·æ现æžã«ãããŠãåºçºç©è³ªãšããŠçšã
ãããã第ïŒå·¥çšã«ãããŠãåŒïŒïŒã®ååç©
ããããªãžã³äžã§å¡©åã¢ã»ãã«ãšåå¿ããããå
å¿æéã¯é·ãïŒïŒå€ïŒããããåŒïŒïŒ
ã®ïŒâã¢ã»ããã·âïŒïŒïŒâã¡ããã·ããšãã«ïŒâ
ïŒïŒïŒâãžãããâïŒïŒïŒâãã³ãŸãã¢ãŒãã³â
ïŒïŒ5HïŒâãªã³ãåç71ïŒ
ã§åœ¢æãããã次ãã§
æãŸããæçµçæç©ã¯ãåŸè
ã®ååç©ãçé
žã«ãª
ãŠã ã®ååšäžã«ã¢ã»ãã³äžã§å¡©åïŒâãžã¡ãã«ã¢
ãããšãã«å¡©é
žå¡©ã§ã¢ã«ãã«åããããšã«ãã€ãŠ
補é ãããããã®æäœã®æ¬ ç¹ã¯ãã¢ã»ãã«åãé«
䟡ãªæ¯æ§æº¶åªã§ããããªãžã³äžã§è¡ãããããã
åå¿æéãããé·ãããšã§ãããããã«é«åžæ¹¿æ§
ã®å¡©åïŒâãžã¡ãã«ã¢ãããšãã«å¡©é
žå¡©ã®äœ¿çš
ã¯ãåå¿äœã®ç§€éã®äžæ£ç¢ºã®ãããªå€ãã®æè¡ç
åé¡ã®åå ãšãªããã
åŒïŒïŒã®ããããªã³é
žèªå°äœãŸãã¯ããªãž
ã³ã第äžã¢ãã³ãã¢ã«ã«ãªéå±ãŸãã¯ã¢ã«ã«ãªå
é¡éå±ããã€ãŠåœ¢æããããã®å¡©ã¯ãå
¬åããã
æ¥æ¬ã®ç¹é¡571365â81å·æ现æžã«é瀺ãããæ¹æ³
ã«ãããŠåºçºåæãšããŠçšãããããããã«è©³ã
ãã¯ãåèšå¡©ã®äœããããžã¡ãã«ãã«ã ã¢ããäž
ã§ç¡æ°Žé
¢é
žã§ã¢ã»ãã«åããããšã«ãã€ãŠãåŒ
ïŒïŒã®ã¢ã»ãã«èªå°äœãåŸããããã®ã¢ã»ãã«
èªå°äœã次ãã§ã¯ãããã°ã©ãã€ãŒã«ãã€ãŠç²Ÿè£œ
ããã次ã«ãåŒïŒïŒã®äžéäœããæ°ŽçŽ åãããª
ãŠã ããã³ã·ãªã«ã²ã«ã®ååšäžã«ãžã¡ãã«ã¹ã«ã
ãã·ãäžã§å¡©åïŒâãžã¡ãã«ã¢ãããšãã«ã®ãšãŒ
ãã«æº¶æ¶²ã«ãã€ãŠåŒïŒïŒã®æçµçæç©ã«åç77
ïŒ
ã§å€æããããã¯ãããã°ã©ãã€ãŒç²Ÿè£œã«å ã
ãŠããã®æ¹æ³ã®ãã以äžã®æ¬ ç¹ã¯ãå±éºãªç©è³ª
ïŒããªãžã³ããžã¡ãã«ã¹ã«ããã·ããæ°ŽçŽ åãã
ãªãŠã ïŒããã³æº¶åªæ··åç©ã®äœ¿çšã§ããã
æ¬çºæã®ç®çã¯ãïŒ2SïŒ3SïŒâïŒâã¢ã»ããã·
âïŒâïŒïŒ®ïŒïŒ®âãžã¡ãã«ã¢ãããšãã«ïŒâïŒâ
ïŒïŒâã¡ããã·âããšãã«ïŒâïŒïŒïŒâãžãããâ
ïŒïŒïŒâãã³ãŸãã¢ãŒãã³âïŒïŒ5HïŒâãªã³ãã
ã³ãã®é
žä»å å¡©ã奜ãŸããã¯ãã®å¡©é
žå¡©ã®æ°ãã
補é æ¹æ³ãæäŸããããšã§ããããã®è£œé æ¹æ³ã«
ããããããã®ååç©ã¯ãåœæ¥çã§æ¢ç¥ã®æäœã«
é¢ããŠè¿°ã¹ãåé¡ãªãäžå±€è¯åçã§å®¹æã«åŸãã
ãææãäžå±€å±éºã§ãªãåå¿äœãçšããŠè£œé ã§ã
ãã
æ¬çºæè
ãã¯ãåŒïŒïŒã®ååç©ããã³åŒ
ïŒïŒã®ååç©ã®äž¡è
ãåã«ïŒâãžã¡ãã«ã¢ãã
ãšã¿ããŒã«ã¡ã·ã¬ãŒãå¡©é
žå¡©ãã¢ã«ãã«åå€ãšã
ãŠçšããããšã«ãã€ãŠãåŸæ¥æ¢ç¥ã®ã¢ã«ãã«åæ
äœã«é¢ããåèšã®å°é£ãªããåªããåçã§ã¢ã«ã
ã«åã§ããããšãå®éšçã«èŠãã ããããã®åå
ç©ã¯ããã®è£œé ã«ã€ããŠåœæ¥çã«ãããŠæ¢ç¥ã®æ
äœã«åŸããå¡©åïŒâãžã¡ãã«ã¢ãããšãã«å¡©é
žå¡©
ãããäžå±€å®¹æã«ãããå®å
šã«å®¹æã«å
¥æã§ãã
ïŒâãžã¡ãã«ã¢ããâãšã¿ããŒã«ããã¡ã¿ã³ã¹ã«
ãã³é
žå¡©åç©ãçšããŠã補é ã§ãããªãŒã¬ãã
ã¯ã»ã·ã³ã»ã·ãŒãºïŒ»Org.Synt.31 37ïŒ151ïŒã
åç
§ããããããžã¡ãã«ã¢ãããšã¿ããŒã«ã¡ã·
ã¬ãŒãå¡©é
žå¡©ã¯ãåœæ¥çã«æ¢ç¥ã®æ¹æ³ã«ãããŠè£œ
é ããããžã€ãŒãã«ã»ãªãã»ã¡ãã€ã·ãã«ã»ã±
ãã¹ããªãŒïŒJ.Med.Chem.ïŒã344ïŒ1966ïŒïŒœããã
ããããšãŒãã«å溶åªãäŸãã°ãžãšãã«ãšãŒã
ã«ããžã€ãœãããã«ãšãŒãã«ãŸãã¯ããã©ããã
ãã©ã³äžã§è£œé ãããããªããªãã°ããã®æ¹æ³ã«
ãããŠã¯ãžã¡ãã«ã¢ãããšã¿ããŒã«ã¡ã·ã¬ãŒãå¡©
é
žå¡©ãäžå±€é«çŽåºŠã§åŸãããããã§ããããã以
äžã®å©ç¹ã¯ããã®ãžã¡ãã«ã¢ãããšã¿ããŒã«ã¡ã·
ã¬ãŒãå¡©é
žå¡©ããåžæ¹¿æ§ã§ãªããåŸã€ãŠãã®è²¯èµ
ããã³åãæ±ãããåœæ¥çã«æ¢ç¥ã®ã¢ã«ãã«åå€
ã®å Žåãããäžå±€å®¹æãªããšã§ããã
ããã«ãæ¬çºæè
ãã¯ãåŸæ¥æ¢ç¥ã®ã¢ã»ãã«å
åå¿ã«é¢ããæ¬ ç¹ã¯ãé
žè§Šåªã®ååšäžã«é
¢é
žã€ãœ
ããããã«ãã¢ã»ãã«åå€ãšããŠçšããããšã«ã
ã€ãŠåé¿ã§ããããšãèŠãã ããããã®åå¿äœã
çšããããšã«ãã€ãŠãçžåœããã¢ã»ãã«èªå°äœ
ã¯ãåŒïŒïŒã®ååç©ããã³åŒïŒïŒã®ååç©ã®
äž¡è
ããéåžžã«çæéã«äºå®äžå®éçã«è£œé ã§ã
ãã
åŸã€ãŠãæ¬çºæã¯ãäžèšã¢ã«ãã«åãïŒâãžã¡
ãã«ã¢ãããšã¿ããŒã«ã¡ã·ã¬ãŒãå¡©é
žå¡©ã§è¡ãã
ãã³ïŒãŸãã¯ïŒäžèšã¢ã»ãã«åãé
¢é
žã€ãœããã
ãã«ã§è¡ãããšãç¹åŸŽãšããã
ïœïŒä»»æã®é åºã§ãåŒïŒïŒ
ã®ïŒ2SïŒ3SïŒâïŒâããããã·âïŒâïŒïŒâã¡
ããã·ããšãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒ
âãã³ãŸãã¢ãŒãã³âïŒïŒ5HïŒâãªã³ãã¢ã«ã
ã«åããã³ã¢ã»ãã«åãããããã¯
ïœïŒ åŒïŒïŒ
ã®ïŒâã¢ã»ããã·âïŒâïŒïŒâã¡ããã·âããš
ãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒâãã³ãŸã
ã¢ãŒãã³âïŒïŒ5HïŒâãªã³ãã¢ã«ãã«åããã
ããŠ
ææãªãã°ãåŸãããåŒïŒïŒã®ååç©ãã
ã®é
žä»å å¡©ã«å€æããããšã«ãããåŒïŒïŒ
ã®ïŒ2SïŒ3SïŒâïŒâã¢ã»ããã·âïŒâïŒïŒ®ïŒïŒ®
âãžã¡ãã«ã¢ãããšãã«ïŒâïŒâïŒïŒâã¡ããã·
ããšãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒâãã³
ãŸãã¢ãŒãã³âïŒïŒ5HïŒâãªã³ããã³ãã®é
žä»
å å¡©ã®æ°ãã補é æ¹æ³ã«é¢ããã
æ¬çºæã®æ¹æ³ã®å¥œãŸããæ
æ§ã«ããã°ãåŒ
ïŒïŒã®ååç©ã¯ãåŒïŒïŒã®ååç©ããåºçºã
ãŠè£œé ããããããŠã¢ã«ãã«åå·¥çšã«ãããŠãïŒ
âãžã¡ãã«ã¢ãããšã¿ããŒã«ã¡ã·ã¬ãŒãå¡©é
žå¡©ã
ã¢ã«ãã«åå€ãšããŠçšããããäžæ¹ã§ã¯ã¢ã»ãã«
åã¯é
žè§Šåªã®ååšäžã«é
¢é
žã€ãœããããã«ã§è¡ã
ããã
第ïŒå·¥çšã«ããããã®æäœã®å€åœ¢ã«ããã°ãã¢
ã«ãã«åã¯ãåèšã®åå¿äœããã€ãŠè¡ããããã®
åŸåŸãããååç©ãé
¢é
žã€ãœããããã«ã§ã¢ã»ã
ã«åãããããããã¯é
žè§Šåªã®ååšäžã«åŒïŒïŒ
ã®ååç©ããŸãé
¢é
žã€ãœããããã«ã§ã¢ã»ãã«å
ãã次ãã§åŸãããååç©ãããã«ïŒâãžã¡ãã«
ã¢ãããšã¿ããŒã«ã¡ã·ã¬ãŒãå¡©é
žå¡©ãšåå¿ãã
ããé
žè§ŠåªãšããŠãäŸãã°ã¹ã«ãã³é
žã奜ãŸãã
ã¯ã¡ã¿ã³ã¹ã«ãã³é
žãŸãã¯ïœâãã«ãšã³âã¹ã«ã
ã³é
žã䜿çšã§ããã
æ¬çºæã¯ãç°¡åãªåå¿æ¡ä»¶äžã«åå¿äžã«åœ¢æã
ããã¢ã»ãã³ã®é£ç¶è±é¢ãªãè¿
éã«å¥œåçã§ïŒ¯â
ã¢ã»ãã«åããé
¢é
žã€ãœããããã«ãããªãã¡ã¢
ã»ãã³ã®ãšããŒã«ã¢ã»ããŒããçšããŠå®æœã§ãã
ãšããçºèŠã«åºã¥ããŠãããããã«ãïŒïŒ®âãž
ã¡ãã«ã¢ãããšãã«åºã¯ã補é ã容æã§ãããäœ
ãäžå¿«ãªæ§è³ªã®ãªãïŒâãžã¡ãã«ã¢ãããšã¿ããŒ
ã«ã¡ã·ã¬ãŒãå¡©é
žå¡©ã«ãã€ãŠå®¹æã«åœ¢æã§ããã
ãšãåãã€ããåå¿ã®åçã¯é«ãã
åå¿ã®ç¹ã«å¥œãŸããæ
æ§ã«ããã°ãã¢ã»ãã³
äžãçé
žã«ãªãŠã ã®ååšäžãéæµäžã«åŒïŒïŒã®
ååç©ïŒã¢ã«ãïŒâãžã¡ãã«âã¢ãããšã¿ããŒã«
ã¡ã·ã¬ãŒãå¡©é
žå¡©1.2ã¢ã«ãïŒã¢ã«ã§ã¢ã«ãã«å
ãããããã®åŸãç¡æ©ç©è³ªããã³ã¢ã»ãã³ãé€
ãããããŠã¡ã¿ã³ã¹ã«ãã³é
žãŸãã¯ïœâãã«ãšã³
âã¹ã«ãã³é
žã®ååšäžã«ã奜ãŸããã¯åŸè
ã®åå
ç©ãïŒã¢ã«åœéã§çšããŠãå¡©çŽ åçåæ°ŽçŽ ã奜ãŸ
ããã¯ãžã¯ãããšã¿ã³ã§è£œé ããã溶液äžã§åŸã
ããåŒïŒïŒã®ååç©ããé
¢é
žã€ãœããããã«ïŒ
ã¢ã«ã3.2ã¢ã«ã§ãã¢ã»ãã«åãããçæç©ãã
ãã®å¡©é
žå¡©ãšããŠåé¢ããã
æ¬çºæã«ããæ¹æ³ã®ä»ã®ç¹ã«å¥œãŸããæ
æ§ã«ã
ãã°ãäžæŽ»æ§æº¶åªäžã§ãïœâãã«ãšã³âã¹ã«ãã³
é
žãŸãã¯ã¡ã¿ã³âã¹ã«ãã³é
žïŒã¢ã«åœéæªæºã®å
åšäžã«åŒïŒïŒã®ååç©ïŒã¢ã«ãé
¢é
žã€ãœããã
ãã«ïŒã¢ã«ã2.2ã¢ã«ã§ã¢ã»ãã«åããã溶åªã
é€ãã次ãã§åŸãããçæç©ãæ¿æ°Žé
žåã¢ã³ã¢ã
ãŠã ã§åŠçãããåŸãããåŒïŒïŒã®ååç©ã次
ã«åèšã®ããã«ããŠïŒâãžã¡ãã«ã¢ãããšã¿ããŒ
ã«ã¡ã·ã¬ãŒãå¡©é
žå¡©1.2ã¢ã«ãïŒã¢ã«ã§ã¢ã«ãã«
åãããçæç©ãããã®å¡©é
žå¡©ã®åœ¢ã§åé¢ããã
æ¬çºæã«ããæ¹æ³ã®æãéèŠãªå©ç¹ã¯ãäžèšã®
ãšããã§ããïŒ
âç¹å¥ã®è£
眮ãèŠããªãã
âæçµçæç©ã¯ç°¡åãªæè¡ããã³å®¹æã«å
¥æã§ã
ãåå¿äœãçšããŠãè¯å¥œãªåçãšãšãã«é«çŽåºŠ
ã§åŸãããã
âäžéäœãåå¿äžã«åé¢ããå¿
èŠããªãã
âåå¿ãå®æœããå Žåãäžå¿«ãªæ§è³ªãæããå±éº
ãªåå¿äœãŸãã¯æº¶åªã䜿çšããªãã
æ¬çºæã«ããæ¹æ³ã®ãã以äžã®è©³çŽ°ã¯ãäžèšã®
ééå®äŸã«ãã€ãŠå
·äœçã«èª¬æãããã
äŸ ïŒ
ïŒ2SïŒ3SïŒâïŒâããããã·âïŒâïŒïŒâã¡ã
ãã·ããšãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒâã
ã³ãŸãã¢ãŒãã³âïŒïŒ5HïŒâãªã³1.5ïœïŒ0.005ã¢
ã«ïŒã50cm3äžžåºãã©ã¹ã³ã«ç§€åãã次ãã§ãžãªã
ãµã³15cm3ã«æº¶è§£ãããã®åŸïœâãã«ãšã³âã¹ã«ã
ã³é
ž0.15ïœããã³é
¢é
žã€ãœããããã«1.1ïœïŒ1.2
cm3ã0.011ã¢ã«ïŒã溶液ã«å ãããåå¿æ··åç©ãã
æªæããªãããïŒæééæµããç空äžã§èžçºãã
次ãã§æ®çç©ãæ¿æ°Žé
žåã¢ã³ã¢ããŠã 氎溶液ïŒcm3
ã§ç²ç ãããåŸãããïŒ2SïŒ3SïŒâïŒâã¢ã»ãã
ã·âïŒâïŒïŒâã¡ããã·ããšãã«ïŒâïŒïŒïŒâãžã
ããâïŒïŒïŒâãã³ãŸãã¢ãŒãã³âïŒïŒ5HïŒâãª
ã³ããå¥ããäžæ§ãŸã§æ°ŽæŽãã次ãã§ä¹Ÿç¥ããã
åéïŒ1.71ïœïŒ99ïŒ
ïŒ
èç¹ïŒ150âã152â
äŸ ïŒ
ïŒ2SïŒ3SïŒâïŒâã¢ã»ããã·âïŒâïŒïŒâã¡ã
ãã·ããšãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒâã
ã³ãŸãã¢ãŒãã³âïŒïŒ5HïŒâãªã³1.70ïœïŒ0.005ã¢
ã«ïŒãã¢ã»ãã³50cm3ã«æº¶è§£ãããããŠïŒâãžã¡ã
ã«ã¢ãããšã¿ããŒã«ã¡ã·ã¬ãŒãå¡©é
žå¡©1.52ïœ
ïŒ0.0075ã¢ã«ïŒããã³çé
žã«ãªãŠã 2.08ïœïŒ0.015
ã¢ã«ïŒã溶液ã«å ãããåŸãããæžæ¿æ¶²ãæªæã
ãªãã12æééæµãããå·åŽã®éã«åå¿æ··åç©ã
ãåé¢ããäžæº¶æ§å¡©ããå¥ãã次ãã§ã液ãèžçº
ãããæ®çç©ãã¯ãããã«ã 20cm3ã«æº¶è§£ãããã
ãŠãšã¿ããŒã«äžã®å¡©é
žã®èšç®éã溶液ã«å ããã
溶液ãç空äžã§èžçºãããããŠæ®çç©ãã€ãœãã
ãããŒã«15cm3ããçµæ¶åãããçµæ¶ãžã«ãã¢ãŒã
å¡©é
žå¡©ããå¥ãã次ãã§ä¹Ÿç¥ããã
åéïŒ1.8ïœïŒ79.92ïŒ
ïŒ
èç¹ïŒ206âã207â
äŸ ïŒ
ïŒ2SïŒ3SïŒâïŒâããããã·âïŒâïŒïŒâã¡ã
ãã·ããšãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒâã
ã³ãŸãã¢ãŒãã³âïŒïŒ5HïŒâãªã³4.5ïœïŒ0.015ã¢
ã«ïŒãã¢ã»ãã³80cm3ã«æº¶è§£ãããããŠïŒâãžã¡ã
ã«ã¢ãããšã¿ããŒã«ã¡ã·ã¬ãŒãå¡©é
žå¡©4.58ïœ
ïŒ0.0225ã¢ã«ïŒããã³çé
žã«ãªãŠã 6.25ïœïŒ0.045
ã¢ã«ïŒã溶液ã«å ãããæžæ¿æ¶²ãæªæããªãã12
æééæµãã宀枩ã«å·åŽãããããŠäžæº¶æ§ç©è³ªã
ãå¥ãããã液ãèžçºããæ®çç©ãã¯ãããã«ã
25cm3ã«æº¶è§£ãããããŠæº¶æ¶²ããšã¿ããŒã«äžå¡©é
žæº¶
液ã®èšç®éã§é
žæ§ã«ãããèžçºåŸãæ®çç©ãã€ãœ
ãããããŒã«20cm3ããçµæ¶åããŠãçµæ¶åœ¢ã®
ïŒ2SïŒ3SïŒâïŒâïŒïŒâãžã¡ãã«ã¢ãããšãã«ïŒâ
ïŒâããããã·âïŒâïŒïŒâã¡ããã·ããšãã«ïŒâ
ïŒïŒïŒâãžãããâïŒïŒïŒâãã³ãŸãã¢ãŒãã³â
ïŒïŒ5HïŒâãªã³å¡©é
žå¡©ãçããããã®åŸãçµæ¶ã
ãéãã次ãã§ä¹Ÿç¥ããã
åéïŒ5.25ïœïŒ85.68ïŒ
ïŒ
èç¹ïŒ225âã227â
α20 DïŒïŒ176.5ãïŒïœïŒ0.7ïŒã¯ãããã«ã ïŒ
äŸ ïŒ
ïŒ2SïŒ3SïŒâïŒâïŒïŒâãžã¡ãã«âã¢ãããšã
ã«ïŒâïŒâããããã·âïŒâïŒïŒâã¡ããã·ããšã
ã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒâãã³ãŸãã¢ãŒ
ãã³âïŒïŒ5HïŒâãªã³å¡©é
žå¡©4.08ïœïŒ0.01ã¢ã«ïŒã
ã¯ãããã«ã 60cm3ã«æº¶è§£ãããã®åŸé
¢é
žã€ãœãã
ããã«3.0ïœïŒ3.3cm3ã0.3ã¢ã«ïŒããã³ã¡ã¿ã³ã¹ã«
ãã³é
ž2.88ïœïŒ1.97cm3ã0.03ã¢ã«ïŒã溶液ã«å ã
ãã次ã«ãã®æº¶æ¶²ã45åéæµãã宀枩ã«å·åŽãã
ãããŠ1næ°Žé
žåãããªãŠã 氎溶液31cm3ã§æœåºã
ããææ©çžã也ç¥ãããšã¿ããŒã«äžå¡©é
žæº¶æ¶²ã®èš
ç®éãå ãããããŠæ··åç©ãèžçºãããæ®çç©ã
ã€ãœãããããŒã«20cm3ããçµæ¶åãããæ²æ®¿ãã
ãžã«ãã¢ãŒã å¡©é
žå¡©çµæ¶ããéãããããŠä¹Ÿç¥ã
ãã
åéïŒ4.0ïœïŒ88.8ïŒ
ïŒ
èç¹ïŒ206âã207â
α20 DïŒïŒ96ãïŒïœïŒ0.5ãã¡ã¿ããŒã«ïŒ
äŸ ïŒ
ïŒ2SïŒ3SïŒâïŒâããããã·âïŒâïŒïŒâã¡ã
ãã·ããšãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒâã
ã³ãŸãã¢ãŒãã³âïŒïŒ5HïŒâãªã³3.0ïœïŒ0.01ã¢ã«ïŒ
ãã¢ã»ãã³80cm3ã«æº¶è§£ãããã®åŸãïŒâãžã¡ãã«
ã¢ãããšã¿ããŒã«ã¡ã·ã¬ãŒãå¡©é
žå¡©3.05ïœ
ïŒ0.015ã¢ã«ïŒããã³çé
žã«ãªãŠã 4.17ïœïŒ0.03ã¢
ã«ïŒã溶液ã«å ãããåŸãããæžæ¿æ¶²ãæªæããª
ãã12æééæµãããå·åŽåŸãäžæº¶æ§ç©è³ªããå¥
ãã次ã«ã液ãç空äžã§èžçºãããæ®çæ²¹ããžã¯
ãããšã¿ã³30cm3ã«æº¶è§£ãããããŠé
¢é
žã€ãœããã
ãã«2.2ïœïŒ2.42cm3ã0.022ã¢ã«ïŒããã³ã¡ã¿ã³ã¹
ã«ãã³é
ž2.11ïœïŒ1.42cm3ã0.022ã¢ã«ïŒã溶液ã«å
ããã溶液ã45å沞隰ãããå·åŽãããããŠ1n
æ°Žé
žåãããªãŠã 氎溶液22cm3ã§æœåºãããææ©çž
ã也ç¥ããèžçºããããããŠæ®çç©ãã€ãœããã
ããŒã«20cm3ããçµæ¶åãããæ²æ®¿ãããžã«ãã¢ãŒ
ã å¡©é
žå¡©çµæ¶ããéãã次ãã§ä¹Ÿç¥ããã
åéïŒ3.21ïœïŒ71.3ïŒ
ïŒ
èç¹ïŒ210âã211â
α20 DïŒïŒ95.81ãïŒïœïŒ0.4ãã¡ã¿ããŒã«ïŒ
äŸ ïŒ
ïŒâãžã¡ãã«ã¢ãããšã¿ããŒã«ã¡ã·ã¬ãŒãå¡©é
ž
å¡©ã®è£œé
ïŒâãžã¡ãã«ã¢ãããšã¿ããŒã«8.9ïœïŒ10.2cm3ã
0.1ã¢ã«ïŒããžã€ãœãããã«ãšãŒãã«100cm3ã«æº¶è§£
ãããã®åŸæªæããªããã枩床ïŒâãïŒâã«ãã
ãŠã¡ã¿ã³ã¹ã«ãã³é
žå¡©åç©12.68ïœïŒïŒcm3ã0.11
ã¢ã«ïŒã溶液ã«æ»Žå ãããããã«10åæªæåŸãç
æç©ããå¥ããã湿最ç©è³ªããšã¿ããŒã«25cm3ãã
åçµæ¶åãããããŠå®€æž©ã«ãããŠä¹Ÿç¥ããã
åéïŒ14.5ïœïŒ72.74ïŒ
ïŒ
èç¹ïŒ126âã127â DETAILED DESCRIPTION OF THE INVENTION The present invention is based on the formula () (2S,3S)-3-acetoxy-5-(N,N-
The present invention relates to a new method for producing dimethylamino-ethyl)-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)one and its acid addition salt. The compound of formula () by its generic name diltiazem is a cardiac drug with calcium antagonist activity. In many methods of producing diltiazem known in the art, it is produced in more reaction steps by the reaction of 2-amino-thiophenol and transmethyl 3-(4-methoxyphenyl)-oxirane-2-carboxylate. expression () (2S,3S)-3-(2-aminophenyl-thio)
-2-hydroxy-3-(4-methoxyphenyl)
-propionic acid or the formula prepared from it () (2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one is used as starting material. According to certain methods of preparing compounds of formula (), for example Hungarian Patent No. 159671 (Belgium Patent No. 723035) and the publication Pharmaceutical Journal
93, 729 (1973) and Helv. Chim. Acta 67 , 916 (1984), the racemate of the compound of formula () is first treated with an alkali metal hydride, preferably sodium hydride. The resulting salt is converted into a 2-dimethylaminoethyl halide, preferably 2-dimethylaminoethyl chloride.
Alkylated with dimethyl-aminoethyl and then obtained as a racemic compound of formula () 5-(2-dimethylaminoethyl)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepine-4(5H)-
ion was acetylated with acetic anhydride. According to the example,
The yield of the alkylation step varies over a wide range (12.4% to 84%
%) and its technical realization was accompanied by many difficulties. Equimolar amounts of sodium hydride are required to bring the compound of formula () into the anionic form and to bind the chloride ion. Because of its flammability, sodium hydride can be mixed with mineral oil (40% to 50%
%) stored under. The presence of traces of mineral oil in the reaction mixture is therefore unavoidable. Traces of oil are present in the resulting 5-(2-dimethylaminoethyl)-3-hydroxy-2-(4-methoxyphenyl)-2,3
-dihydro-1,5-benzothiazepine-4
The (5H)-one can only be removed by introducing it into the aqueous phase in the form of its salt. Another disadvantage of the reaction is the use of 2-dimethylaminoethyl chloride in the alkylation step, which is added to an anhydrous organic solution due to the aforementioned properties of sodium hydride. 2-dimethylaminoethylethyl chloride is
They are known to be prone to self-quaternization (during "head-to-tail" reactions), which poses a difficult problem on a large scale. This is because the products of the quaternization reaction precipitate from solutions prepared with ether solutions or other inert solvents, thereby shifting the reaction towards by-product formation. As mentioned above and according to the above reference, the compound of formula () is converted to the final product of formula () with acetic anhydride at 90° to 100°C. Although this process appears to be without any difficulties, the yields obtained are only 80%-84%, and problems with regeneration of reactants used in excess are made more difficult by the presence of acetic acid. It can be seen from this that even this process does not fully meet the requirements of the developed industrially applicable operation. Compounds of formula () are also used as starting materials in European Patent Application No. 81234. In the first step, a compound of formula () was reacted with acetyl chloride in pyridine. The reaction time is long (one night), and the formula () 3-acetoxy-2(4-methoxyphenyl)-
2,3-dihydro-1,5-benzothiazepine-
4(5H)-one was formed in 71% yield. The desired final product was then prepared by alkylation of the latter compound with 2-dimethylaminoethyl chloride hydrochloride in acetone in the presence of potassium carbonate. The disadvantage of this procedure is that the acetylation is carried out in pyridine, an expensive and toxic solvent, and the reaction time is rather long. Furthermore, the use of highly hygroscopic 2-dimethylaminoethyl chloride hydrochloride would cause many technical problems, such as inaccuracies in the weighing of reactants. Propionic acid derivatives of formula () or their salts formed with pyridine, tertiary amines, alkali metals or alkaline earth metals can be prepared in the process disclosed in published Japanese Patent Application No. 571,365-81. It was used as a starting material. More specifically, acetylation of any of the above salts with acetic anhydride in dimethylformamide gave an acetyl derivative of formula (), which was then purified by chromatography. The intermediate of formula () is then converted to the final product of formula () by an ethereal solution of 2-dimethylaminoethyl chloride in dimethyl sulfoxide in the presence of sodium hydride and silica gel in a yield of 77.
Converted in %. In addition to the chromatographic purification, further disadvantages of this method are the use of hazardous substances (pyridine, dimethyl sulfoxide, sodium hydride) and solvent mixtures. The object of the present invention is (2S,3S)-3-acetoxy-5-(N,N-dimethylaminoethyl)-2-
(4-methoxy-phenyl)-2,3-dihydro-
The object of the present invention is to provide a new method for the preparation of 1,5-benzothiazepin-4(5H)-one and its acid addition salts, preferably its hydrochloride, by which these compounds can be prepared using easily obtainable materials, less hazardous reactants, and in better yields without the problems mentioned with respect to the operation. The inventors have determined that both the compound of formula () and the compound of formula () can be prepared by simply using 2-dimethylaminoethanol mesylate hydrochloride as the alkylating agent, as described above with respect to previously known alkylation operations. It has been experimentally found that the alkylation can be carried out without difficulty and in excellent yields. This compound was prepared using methanesulfonic acid chloride from 2-dimethylamino-ethanol, which is more readily and safely available than 2-dimethylaminoethyl chloride hydrochloride, following procedures known in the art for its preparation. , can be manufactured [see Organic Synthesis [Org. Synt.] 31 37 (151)]. Dimethylaminoethanol mesylate hydrochloride is prepared by methods known in the art [J.Med.Chem. 9 , 344 (1966)], but by
However, they are prepared in ethereal solvents, such as diethyl ether, diisopropyl ether or tetrahydrofuran. This is because dimethylaminoethanol mesylate hydrochloride can be obtained with higher purity in this method. A further advantage is that this dimethylaminoethanol mesylate hydrochloride is not hygroscopic and therefore its storage and handling is easier than with alkylating agents known in the art. Furthermore, the inventors have found that the drawbacks associated with previously known acetylation reactions can be avoided by using isopropenyl acetate as the acetylating agent in the presence of an acid catalyst. By using this reactant, the corresponding acetyl derivatives can be prepared virtually quantitatively in a very short time from both compounds of formula () and compounds of formula (). The invention is therefore characterized in that the following alkylation is carried out with 2-dimethylaminoethanol mesylate hydrochloride and/or the following acetylation is carried out with isopropenyl acetate: a) In any order, the formula ( ) (2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5
-benzothiazepine-4(5H)-one is alkylated and acetylated, or b) formula () of 3-acetoxy-2-(4-methoxy-phenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one and, if desired, the resulting formula () By converting the compound of formula () into its acid addition salt (2S,3S)-3-acetoxy-5-(N,N
-Dimethylaminoethyl)-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one and its acid addition salt. According to a preferred embodiment of the process of the invention, a compound of formula () is prepared starting from a compound of formula () and in the alkylation step 2
-Dimethylaminoethanol mesylate hydrochloride is used as alkylating agent, while acetylation is carried out with isopropenyl acetate in the presence of an acid catalyst. According to a variant of this procedure in the first step, the alkylation is carried out with the abovementioned reactants and the compound obtained is then acetylated with isopropenyl acetate or in the presence of an acid catalyst of the formula ( )
The compound is first acetylated with isopropenyl acetate and then the resulting compound is further reacted with 2-dimethylaminoethanol mesylate hydrochloride. As acid catalyst it is possible to use, for example, sulfonic acids, preferably methanesulfonic acid or p-toluene-sulfonic acid. The present invention enables O-
It is based on the discovery that acetylation can be carried out using isopropenyl acetate, the enol acetate of acetone. Furthermore, it has been found that the N,N-dimethylaminoethyl group can be easily formed with 2-dimethylaminoethanol mesylate hydrochloride, which is easy to prepare and has no unpleasant properties. The yield of the reaction is high. According to a particularly preferred embodiment of the reaction, 1 mol of a compound of formula () is alkylated with 1.2 mol to 2 mol of 2-dimethyl-aminoethanol mesylate hydrochloride in acetone in the presence of potassium carbonate under reflux. Thereafter, the inorganic substances and acetone are removed and a chlorinated hydrocarbon, preferably dichloroethane, is prepared in the presence of methanesulfonic acid or p-toluene-sulfonic acid, preferably using 1 molar equivalent of the latter compound. The compound of formula () obtained in solution was added to isopropenyl acetate 2
mol ~ 3.2 mol, acetylates. the product,
It is isolated as its hydrochloride salt. According to another particularly preferred embodiment of the process according to the invention, 1 mole of a compound of formula Acetylation occurs between 2 mol and 2.2 mol. The solvent is removed and the product obtained is then treated with concentrated ammonium hydroxide. The resulting compound of formula () is then alkylated with 1.2 to 2 moles of 2-dimethylaminoethanol mesylate hydrochloride as described above. The product is isolated in its hydrochloride form. The most important advantages of the method according to the invention are: - No special equipment is required. - The final product is obtained in high purity with good yield using simple techniques and readily available reactants. - There is no need to isolate intermediates during the reaction. - When carrying out the reaction, no hazardous reactants or solvents with unpleasant properties are used. Further details of the method according to the invention are illustrated by the following non-limiting examples. Example 1 1.5 g (0.005 mol) of (2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepine-4(5H)-one was added to a 50 cm 3 weighed into a round bottom flask and then dissolved in 15 cm 3 of dioxane, followed by 0.15 g of p-toluene-sulfonic acid and 1.1 g of isopropenyl acetate (1.2
cm 3 , 0.011 mol) is added to the solution. The reaction mixture is
While stirring, reflux for 1 hour, evaporate in vacuo,
The residue was then diluted with 5 cm 3 of concentrated ammonium hydroxide aqueous solution.
Grind with. The obtained (2S,3S)-3-acetoxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one was filtered off and neutralized. Wash with water and then dry. Yield: 1.71g (99%) Melting point: 150â~152â Example 2 (2S,3S)-3-acetoxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepine -4(5H)-one 1.70 g (0.005 mol) was dissolved in 50 cm 3 of acetone and 1.52 g of 2-dimethylaminoethanol mesylate hydrochloride
(0.0075 mol) and potassium carbonate 2.08 g (0.015 mol)
mol) to the solution. The resulting suspension is refluxed for 12 hours with stirring. The insoluble salts which separated out from the reaction mixture on cooling are filtered off and the filtrate is then evaporated. Dissolve the residue in 20 cm 3 of chloroform and add the calculated amount of hydrochloric acid in ethanol to the solution.
The solution is evaporated in vacuo and the residue is crystallized from 15 cm 3 of isopropanol. The crystalline diltiazem hydrochloride is filtered off and then dried. Yield: 1.8g (79.92%) Melting point: 206â~207â Example 3 (2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepine 4.5 g (0.015 mol) of -4(5H)-one were dissolved in 80 cm 3 of acetone and 4.58 g of 2-dimethylaminoethanol mesylate hydrochloride
(0.0225 mol) and potassium carbonate 6.25 g (0.045
mol) to the solution. 12 while stirring the suspension
Reflux for an hour, cool to room temperature and filter off the insoluble material. Evaporate the filtrate and chloroform the residue.
Dissolve in 25 cm 3 and acidify the solution with the calculated amount of hydrochloric acid solution in ethanol. After evaporation, the residue was crystallized from 20 cm 3 of isopropanol to give the crystalline form (2S,3S)-5-(2-dimethylaminoethyl)-
3-hydroxy-2-(4-methoxyphenyl)-
2,3-dihydro-1,5-benzothiazepine-
4(5H)-one hydrochloride is produced. The crystals are then filtered and then dried. Yield: 5.25g (85.68%) Melting point: 225°C to 227°C [α] 20 D = +176.5° (c = 0.7; chloroform) Example 4 (2S,3S)-5-(2-dimethyl-aminoethyl) 4.08 g (0.01 mol) of -3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepine-4(5H)-one hydrochloride was dissolved in 60 cm 3 of chloroform. , then 3.0 g (3.3 cm 3 , 0.3 mol) of isopropenyl acetate and 2.88 g (1.97 cm 3 , 0.03 mol) of methanesulfonic acid are added to the solution. The solution was then refluxed for 45 minutes, cooled to room temperature,
Then, extract with 31 cm 3 of 1N aqueous sodium hydroxide solution. Dry the organic phase, add the calculated amount of hydrochloric acid solution in ethanol and evaporate the mixture. The residue is crystallized from 20 cm 3 of isopropanol. The precipitated diltiazem hydrochloride crystals are filtered and dried. Yield: 4.0g (88.8%) Melting point: 206°C to 207°C [α] 20 D = +96° (c = 0.5, methanol) Example 5 (2S,3S)-3-hydroxy-2-(4-methoxyphenyl )-2,3-dihydro-1,5-benzothiazepine-4(5H)-one 3.0 g (0.01 mol)
was dissolved in 80 cm 3 of acetone, then 3.05 g of 2-dimethylaminoethanol mesylate hydrochloride
(0.015 mol) and 4.17 g (0.03 mol) of potassium carbonate are added to the solution. The resulting suspension is refluxed for 12 hours with stirring. After cooling, the insoluble material is filtered off and the filtrate is then evaporated in vacuo. The residual oil is dissolved in 30 cm 3 of dichloroethane and 2.2 g (2.42 cm 3 , 0.022 mol) of isopropenyl acetate and 2.11 g (1.42 cm 3 , 0.022 mol) of methanesulfonic acid are added to the solution. Boil the solution for 45 minutes, cool, and add 1n
Extract with 22 cm 3 of aqueous sodium hydroxide solution. The organic phase is dried, evaporated and the residue is crystallized from 20 cm 3 of isopropanol. The precipitated diltiazem hydrochloride crystals are filtered and then dried. Yield: 3.21g (71.3%) Melting point: 210°C to 211°C [α] 20 D = +95.81° (c = 0.4, methanol) Example 6 Production of 2-dimethylaminoethanol mesylate hydrochloride 2-dimethylaminoethanol 8.9g ( 10.2cm3 ,
0.1 mol) in 100 cm 3 of diisopropyl ether and then, with stirring, 12.68 g (8 cm 3 , 0.11 mol) of methanesulfonic acid chloride at a temperature of 0°C to 5°C.
mol) dropwise into the solution. After stirring for a further 10 minutes, the product is filtered off. The wet material is recrystallized from 25 cm 3 of ethanol and dried at room temperature. Yield: 14.5g (72.74%) Melting point: 126â~127â
Claims (1)
ããŒã«ã¡ã·ã¬ãŒãå¡©é žå¡©ã§è¡ããããã³ïŒãŸã
ã¯ïŒäžèšã¢ã»ãã«åãé ¢é žã€ãœããããã«ã§è¡ã
ããšãç¹åŸŽãšããã ïœïŒ ä»»æã®é åºã§åŒïŒïŒ ã®ïŒ2SïŒ3SïŒâïŒâããããã·âïŒâïŒïŒâã¡
ããã·ããšãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒ
âãã³ãŸâãã¢ãŒãã³âïŒïŒ5HïŒâãªã³ãã¢ã«
ãã«åããã³ã¢ã»ãã«åããããã㯠ïœïŒ åŒïŒïŒ ã®ïŒâã¢ã»ããã·âïŒâïŒïŒâã¡ããã·âããš
ãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒâãã³ãŸã
ã¢ãŒãã³âïŒïŒ5HïŒâãªã³ãã¢ã«ãã«åãã ãããŠææãªãã°åŸãããåŒïŒïŒã®ååç©
ããã®é žä»å å¡©ã«å€æããããšã«ãããåŒ
ïŒïŒ ã®ïŒ2SïŒ3SïŒâïŒâã¢ã»ããã·âïŒâïŒïŒ®ïŒïŒ®
âãžã¡ãã«ã¢ãããšãã«ïŒâïŒâïŒïŒâã¡ããã·
âããšãã«ïŒâïŒïŒïŒâãžãããâïŒïŒïŒâã
ã³ãŸãã¢ãŒãã³âïŒïŒ5HïŒâãªã³ããã³ãã®é ž
ä»å å¡©ã®è£œé æ¹æ³ã ïŒ åŒïŒïŒã®ååç©ãïŒâãžã¡ãã«ã¢ãããšã¿
ããŒã«ã¡ã·ã¬ãŒãå¡©é žå¡©ã§ã¢ã«ãã«åãããããŠ
åŸãããåŒïŒïŒ ã®ååç©ãã¢ã»ãã«åå€ãšåå¿ãããããšãç¹åŸŽ
ãšãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®æ¹æ³ã ïŒ åŒïŒïŒã®ååç©ãïŒâãžã¡ãã«ã¢ãããšã¿
ããŒã«ã®åå¿æ§èªå°äœã§ã¢ã«ãã«åãããããŠé ž
觊åªã®ååšäžã«ãåŸãããåŒïŒïŒã®ååç©ãé ¢
é žã€ãœããããã«ã§ã¢ã»ãã«åããããšãç¹åŸŽãš
ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®æ¹æ³ã ïŒ åŒïŒïŒã®ååç©ãã¢ã»ãã«åå€ãšåå¿ã
ãããããŠåŸãããåŒïŒïŒã®ååç©ãïŒâãžã¡
ãã«ã¢ãããšã¿ããŒã«ã¡ã·ã¬ãŒãå¡©é žå¡©ã§ã¢ã«ã
ã«åããããšãç¹åŸŽãšãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é ã«èšèŒã®æ¹æ³ã ïŒ é žè§Šåªã®ååšäžã«åŒïŒïŒã®ååç©ãé ¢é žã€
ãœããããã«ã§ã¢ã»ãã«åãã次ãã§åŸãããåŒ
ïŒïŒã®ååç©ãïŒâãžã¡ãã«ã¢ããâãšã¿ããŒ
ã«ã®åå¿æ§èªå°äœã§ã¢ã«ãã«åããããšãç¹åŸŽãš
ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®æ¹æ³ã ïŒ åŒïŒïŒã®ååç©ãïŒâãžã¡ãã«ã¢ãããšã¿
ããŒã«ã¡ã·ã¬ãŒãå¡©é žå¡©ã§ã¢ã«ãã«åããããŠé ž
觊åªã®ååšäžã«åŸãããåŒïŒïŒã®ååç©ãé ¢é ž
ã€ãœããããã«ã§ã¢ã»ãã«åããããšãç¹åŸŽãšã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®æ¹æ³ã ïŒ é žè§Šåªã®ååšäžã«ãåŒïŒïŒã®ååç©ãé ¢é ž
ã€ãœããããã«ã§ã¢ã»ãã«åãã次ãã§åŸããã
åŒïŒïŒã®ååç©ãïŒâãžã¡ãã«ã¢ãããšã¿ããŒ
ã«ã¡ã·ã¬ãŒãå¡©é žå¡©ã§ã¢ã«ãã«åããããšãç¹åŸŽ
ãšãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®æ¹æ³ã ïŒ åŒïŒïŒã®ååç©ïŒã¢ã«ãïŒâãžã¡ãã«ã¢ã
ããšã¿ããŒã«ã¡ã·ã¬ãŒãå¡©é žå¡©1.2ã¢ã«ãïŒã¢ã«
ã§ã¢ã«ãã«åãããããŠé žè§Šåªã奜ãŸããã¯ã¡ã¿
ã³âã¹ã«ãã³é žãŸãã¯ïœâãã«ãšã³âã¹ã«ãã³é ž
ã®ååšäžã«ãåŸãããåŒïŒïŒã®ååç©ãé ¢é žã€
ãœããããã«ïŒã¢ã«ã3.2ã¢ã«ã§ã¢ã»ãã«åãã
ããšãç¹åŸŽãšãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãŸãã¯
第ïŒé ã«èšèŒã®æ¹æ³ã ïŒ é žè§Šåªã奜ãŸããã¯ã¡ã¿ã³âã¹ã«ãã³é žãŸã
ã¯ïœâãã«ãšã³âã¹ã«ãã³é žã®ååšäžã«åŒïŒïŒ
ã®ååç©ïŒã¢ã«ãé ¢é žã€ãœããããã«ïŒã¢ã«ã
2.2ã¢ã«ã§ã¢ã»ãã«åãã次ãã§åŸãããåŒïŒïŒ
ã®ååç©ãïŒâãžã¡ãã«ã¢ããâãšã¿ããŒã«ã¡ã·
ã¬ãŒãå¡©é žå¡©1.2ã¢ã«ãïŒã¢ã«ã§ã¢ã«ãã«åãã
ããšãç¹åŸŽãšãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãŸãã¯
第ïŒé ã«èšèŒã®æ¹æ³ã[Scope of Claims] 1. characterized in that the following alkylation is carried out with 2-dimethylamino-ethanol mesylate hydrochloride and/or the following acetylation is carried out with isopropenyl acetate, a) in any order of the formula () (2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5
-benzo-thiazepin-4(5H)-one is alkylated and acetylated, or b) formula () of 3-acetoxy-2-(4-methoxy-phenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one and, if desired, the resulting formula () By converting the compound into its acid addition salt, the formula () (2S,3S)-3-acetoxy-5-(N,N
A method for producing -dimethylaminoethyl)-2-(4-methoxy-phenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one and its acid addition salt. 2 A compound of formula () is alkylated with 2-dimethylaminoethanol mesylate hydrochloride, and the resulting formula () 2. A method according to claim 1, characterized in that the compound is reacted with an acetylating agent. 3. Alkylating a compound of formula () with a reactive derivative of 2-dimethylaminoethanol and acetylating the resulting compound of formula () with isopropenyl acetate in the presence of an acid catalyst, A method according to claim 1. 4. Claim 1, characterized in that the compound of formula () is reacted with an acetylating agent and the resulting compound of formula () is alkylated with 2-dimethylaminoethanol mesylate hydrochloride.
The method described in section. 5. Acetylation of a compound of formula () with isopropenyl acetate in the presence of an acid catalyst, and then alkylation of the resulting compound of formula () with a reactive derivative of 2-dimethylamino-ethanol, A method according to claim 1. 6. Claims characterized in that the compound of formula () is alkylated with 2-dimethylaminoethanol mesylate hydrochloride and the compound of formula () obtained in the presence of an acid catalyst is acetylated with isopropenyl acetate. The method described in item 1 of the scope. 7. Acetylating a compound of formula () with isopropenyl acetate in the presence of an acid catalyst, and then alkylating the resulting compound of formula () with 2-dimethylaminoethanol mesylate hydrochloride, A method according to claim 7. 8 1 mole of the compound of formula () is alkylated with 1.2 to 2 moles of 2-dimethylaminoethanol mesylate hydrochloride and in the presence of an acid catalyst, preferably methane-sulfonic acid or p-toluene-sulfonic acid, the obtained 7. The method according to claim 1, wherein the compound of formula () is acetylated with 2 to 3.2 mol of isopropenyl acetate. 9 In the presence of an acid catalyst, preferably methane-sulfonic acid or p-toluene-sulfonic acid, the formula ()
1 mole of the compound is converted into 2 moles of isopropenyl acetate ~
Acetylated with 2.2 mol and then the resulting formula ()
6. Process according to claim 1, characterized in that the compound of 2-dimethylamino-ethanol mesylate hydrochloride is alkylated with 1.2 to 2 mol of 2-dimethylamino-ethanol mesylate hydrochloride.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU854264A HU195795B (en) | 1985-11-06 | 1985-11-06 | Process for preparing (2s,3s)-3-acetoxy-5-(n,n-dimethyl-amino-ethyl)-2-(h-methoxy-phenyl)-2,3-dihydro-1,5-benzothiazepin-h(5h)-one |
HU2251-4264/85 | 1985-11-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS62108872A JPS62108872A (en) | 1987-05-20 |
JPH0354939B2 true JPH0354939B2 (en) | 1991-08-21 |
Family
ID=10967486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61263630A Granted JPS62108872A (en) | 1985-11-06 | 1986-11-05 | Production of dilutiazem |
Country Status (6)
Country | Link |
---|---|
JP (1) | JPS62108872A (en) |
AT (1) | AT393837B (en) |
BE (1) | BE905704A (en) |
CA (1) | CA1309714C (en) |
ES (1) | ES2001146A6 (en) |
HU (1) | HU195795B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6450872A (en) * | 1987-08-21 | 1989-02-27 | Tanabe Seiyaku Co | Production of 1,5-benzothiazepine derivative |
IT1226301B (en) * | 1988-07-26 | 1990-12-27 | Zambon Spa | PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE SYNTHESIS OF DILTIAZEM. |
-
1985
- 1985-11-06 HU HU854264A patent/HU195795B/en not_active IP Right Cessation
-
1986
- 1986-11-05 ES ES8602911A patent/ES2001146A6/en not_active Expired
- 1986-11-05 CA CA000522187A patent/CA1309714C/en not_active Expired - Fee Related
- 1986-11-05 JP JP61263630A patent/JPS62108872A/en active Granted
- 1986-11-05 AT AT0294786A patent/AT393837B/en not_active IP Right Cessation
- 1986-11-05 BE BE0/217372A patent/BE905704A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JPS62108872A (en) | 1987-05-20 |
AT393837B (en) | 1991-12-27 |
HUT42767A (en) | 1987-08-28 |
ATA294786A (en) | 1991-06-15 |
BE905704A (en) | 1987-03-02 |
CA1309714C (en) | 1992-11-03 |
ES2001146A6 (en) | 1988-04-16 |
HU195795B (en) | 1988-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0626952B1 (en) | Hypolipidaemic benzothiazepine compounds | |
KR860002034B1 (en) | Process for preparing benzothiazepine derivatives | |
HU193161B (en) | Process for preparing new n-alkyl-norscopines | |
CZ292579B6 (en) | Process for preparing pure enantiomers of tropic acid esters | |
JPH0354939B2 (en) | ||
JPH0458472B2 (en) | ||
JPH0357895B2 (en) | ||
JP3996228B2 (en) | Process for producing 3-piperazinylbenzisothiazoles | |
JP3018296B2 (en) | Method for producing glycidyl ether | |
WO2005120498A2 (en) | Method for synthesis of lonidamine and related indazole derivatives | |
US4200761A (en) | Process for preparing N-cyano-N'methyl-N"-{2-[(4-methyl-5-imidazolyl)-methylthio]-ethyl} guanidine | |
US4118501A (en) | Thiazolidine derivatives | |
JP2000219688A (en) | Production of heterocyclic compound | |
KR0133056B1 (en) | Process for preparing 1,5-benzothiazepine derivatives | |
US3484452A (en) | 3-amino-4-phenyl-1,2,5-thiadiazole | |
EP0320532A1 (en) | Novel optically active carboxylic acid derivative l-lysine salt and process for production thereof | |
JP2539261B2 (en) | Imidazole derivative | |
JPH05202013A (en) | Preparation of 1,5-benzothiazepine derivative | |
KR810000817B1 (en) | Process for preparing n,n-dimethyl-3-(4-bromophenyl)-3(3-pyridine)-arylamine | |
JP3213746B2 (en) | Process for producing 1,3-dialkyl-5-hydroxyoxindole and its ether derivative | |
JPH10310567A (en) | Crystallization of 3-amino-2-(n-alkoxycarbonyl) aminopropionic acid ester-substituted benzenesulfonic acid salt | |
HU207709B (en) | Process for producing n-/n-propyl/-n-/2-/2,4,6-trichloro-phenoxy/-ethyl/-amine | |
JPS60204776A (en) | 1,5-benzothiazepine derivative | |
JPH0586042A (en) | Process for producing 2-mercapto-phenothiazine | |
US4304929A (en) | Process for preparing 4-(n-hexadecylamino)-benzoic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |